Literature DB >> 30140051

Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Yang Shi1, David M Holtzman2.   

Abstract

Alzheimer disease is more than a pure proteopathy. Chronic neuroinflammation stands out during the pathogenesis of the disease and in turn modulates disease progression. The central nervous system (CNS) is separated from the blood circulation by the blood-brain barrier. In Alzheimer disease, neuroinflammation heavily relies on innate immune responses that are primarily mediated by CNS-resident microglia. APOE (which encodes apolipoprotein E) is the strongest genetic risk factor for Alzheimer disease, and APOE was recently shown to affect the disease in part through its immunomodulatory function. This function of APOE is likely linked to triggering receptor expressed on myeloid cells 2 (TREM2), which is expressed by microglia in the CNS. Here, we review the rapidly growing literature on the role of disease-associated microglia, TREM2 and APOE in the pathogenesis of Alzheimer disease and present an integrated view of innate immune function in Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30140051      PMCID: PMC6425488          DOI: 10.1038/s41577-018-0051-1

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  153 in total

1.  Synaptic pruning by microglia is necessary for normal brain development.

Authors:  Rosa C Paolicelli; Giulia Bolasco; Francesca Pagani; Laura Maggi; Maria Scianni; Patrizia Panzanelli; Maurizio Giustetto; Tiago Alves Ferreira; Eva Guiducci; Laura Dumas; Davide Ragozzino; Cornelius T Gross
Journal:  Science       Date:  2011-07-21       Impact factor: 47.728

2.  Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.

Authors:  Ana Griciuc; Alberto Serrano-Pozo; Antonio R Parrado; Andrea N Lesinski; Caroline N Asselin; Kristina Mullin; Basavaraj Hooli; Se Hoon Choi; Bradley T Hyman; Rudolph E Tanzi
Journal:  Neuron       Date:  2013-04-25       Impact factor: 17.173

Review 3.  Microglia: Dynamic Mediators of Synapse Development and Plasticity.

Authors:  Yuwen Wu; Lasse Dissing-Olesen; Brian A MacVicar; Beth Stevens
Journal:  Trends Immunol       Date:  2015-10       Impact factor: 16.687

4.  Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology.

Authors:  Marie-Victoire Guillot-Sestier; Kevin R Doty; David Gate; Javier Rodriguez; Brian P Leung; Kavon Rezai-Zadeh; Terrence Town
Journal:  Neuron       Date:  2015-01-22       Impact factor: 17.173

5.  APOE ε4 increases risk for dementia in pure synucleinopathies.

Authors:  Debby Tsuang; James B Leverenz; Oscar L Lopez; Ronald L Hamilton; David A Bennett; Julie A Schneider; Aron S Buchman; Eric B Larson; Paul K Crane; Jeffrey A Kaye; Patricia Kramer; Randy Woltjer; John Q Trojanowski; Daniel Weintraub; Alice S Chen-Plotkin; David J Irwin; Jacqueline Rick; Gerard D Schellenberg; G Stennis Watson; Walter Kukull; Peter T Nelson; Gregory A Jicha; Janna H Neltner; Doug Galasko; Eliezer Masliah; Joseph F Quinn; Kathryn A Chung; Dora Yearout; Ignacio F Mata; Jia Y Wan; Karen L Edwards; Thomas J Montine; Cyrus P Zabetian
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

6.  Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.

Authors:  Walter J Brecht; Faith M Harris; Shengjun Chang; Ina Tesseur; Gui-Qiu Yu; Qin Xu; Jo Dee Fish; Tony Wyss-Coray; Manuel Buttini; Lennart Mucke; Robert W Mahley; Yadong Huang
Journal:  J Neurosci       Date:  2004-03-10       Impact factor: 6.167

7.  Allele epsilon 4 of apolipoprotein E shows a dose effect on age at onset of Pick disease.

Authors:  L A Farrer; C R Abraham; L Volicer; E J Foley; N W Kowall; A C McKee; J M Wells
Journal:  Exp Neurol       Date:  1995-12       Impact factor: 5.330

8.  Apolipoprotein E4 is deficient in inducing macrophage ABCA1 expression and stimulating the Sp1 signaling pathway.

Authors:  Emmanuel Ugochukwu Okoro; Yanfeng Zhao; ZhongMao Guo; Lichun Zhou; Xinghua Lin; Hong Yang
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

9.  Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses.

Authors:  P Cunin; C Beauvillain; C Miot; J-F Augusto; L Preisser; S Blanchard; P Pignon; M Scotet; E Garo; I Fremaux; A Chevailler; J-F Subra; P Blanco; M R Wilson; P Jeannin; Y Delneste
Journal:  Cell Death Dis       Date:  2016-05-05       Impact factor: 8.469

10.  ABCA7 Deficiency Accelerates Amyloid-β Generation and Alzheimer's Neuronal Pathology.

Authors:  Nobutaka Sakae; Chia-Chen Liu; Mitsuru Shinohara; Jessica Frisch-Daiello; Li Ma; Yu Yamazaki; Masaya Tachibana; Linda Younkin; Aishe Kurti; Minerva M Carrasquillo; Fanggeng Zou; Daniel Sevlever; Gina Bisceglio; Ming Gan; Romain Fol; Patrick Knight; Miao Wang; Xianlin Han; John D Fryer; Michael L Fitzgerald; Yasumasa Ohyagi; Steven G Younkin; Guojun Bu; Takahisa Kanekiyo
Journal:  J Neurosci       Date:  2016-03-30       Impact factor: 6.167

View more
  132 in total

Review 1.  Impact of dietary polyphenols on neuroinflammation-associated disorders.

Authors:  Neeraja Revi; Aravind Kumar Rengan
Journal:  Neurol Sci       Date:  2021-05-14       Impact factor: 3.307

Review 2.  The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration.

Authors:  Jared T Hinkle; Valina L Dawson; Ted M Dawson
Journal:  Mov Disord       Date:  2019-05-28       Impact factor: 10.338

3.  In Vivo Chimeric Alzheimer's Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons.

Authors:  Ramsey Najm; Kelly A Zalocusky; Misha Zilberter; Seo Yeon Yoon; Yanxia Hao; Nicole Koutsodendris; Maxine Nelson; Antara Rao; Alice Taubes; Emily A Jones; Yadong Huang
Journal:  Cell Rep       Date:  2020-07-28       Impact factor: 9.423

4.  Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model.

Authors:  Robert J Andrew; Pierre De Rossi; Phuong Nguyen; Haley R Kowalski; Aleksandra J Recupero; Thomas Guerbette; Sofia V Krause; Richard C Rice; Lisa Laury-Kleintop; Steven L Wagner; Gopal Thinakaran
Journal:  J Biol Chem       Date:  2019-01-28       Impact factor: 5.157

Review 5.  Evaluation of CD33 as a genetic risk factor for Alzheimer's disease.

Authors:  Steven Estus; Benjamin C Shaw; Nicholas Devanney; Yuriko Katsumata; Eileen E Press; David W Fardo
Journal:  Acta Neuropathol       Date:  2019-04-04       Impact factor: 17.088

Review 6.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Authors:  Justin M Long; David M Holtzman
Journal:  Cell       Date:  2019-09-26       Impact factor: 41.582

Review 7.  Peripheral versus central nervous system APOE in Alzheimer's disease: Interplay across the blood-brain barrier.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Wenhui Qu; Ling Li
Journal:  Neurosci Lett       Date:  2019-06-07       Impact factor: 3.046

Review 8.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

Review 9.  Microbiota in cerebrovascular disease: A key player and future therapeutic target.

Authors:  Shuichi Tonomura; Masafumi Ihara; Robert P Friedland
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-20       Impact factor: 6.200

10.  Common germline variants of the human APOE gene modulate melanoma progression and survival.

Authors:  Benjamin N Ostendorf; Jana Bilanovic; Nneoma Adaku; Kimia N Tafreshian; Bernardo Tavora; Roger D Vaughan; Sohail F Tavazoie
Journal:  Nat Med       Date:  2020-05-25       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.